Design, synthesis and anti-ulcerogenic effect of some of furo-salicylic acid derivatives on acetic acid-induced ulcerative colitis

European Journal of Medicinal Chemistry

Volumn 45, Issue 9, 2010, Pages 4104-4112

  Hassan, Ghaneya S ^a   Soliman, Gamal A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Acetic acid induced ulcerative colitis; Anti ulcerogenic effect; Antimicrobial activity; Furo salicylic acid derivatives; MOE

Indexed keywords

6 HYDROXY 4 METHOXY 7 (2 PHENYLAZO)BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY 4 METHOXY 7 (AMINOSULPHONYL)BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY 4 METHOXY 7 (PHENYLAMINOLSULPHONYL)BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY 4 METHOXY 7 (PHENYLSULPHONAMIDO)BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY 4 METHOXY 7 [(P METHYLPHENYL)AMINOSULPHONYL]BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY 4 METHOXY 7 [(P METHYLPHENYL)SULPHONAMIDO]BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY 4 METHOXY 7 [2 (2 PYRIDINYLSULPHAMOYL) PHENYLAZO]BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY 7 [4 (P METHOXYPHENYL)AMINOSULPHONYL] 4 METHOXMETHOXYBENZOFURAN 5 CARBOXYLIC ACID; 7 (CHLOROSULPHONYL) 6 HYDROXY 4 METHOXYBENZOFURAN 5 CARBOXYLIC ACID; 7 [2 (4 CARBOXY 3 HYDROXY PHENYL) AZO] 6 HYDROXY 4 METHOXYBENZOFURAN 5 CARBOXYLIC ACID; 7 [4 (2,4 DICHLOROPHENYL)AMINOSULPHONYL] 6 HYDROXY 4 METHOXYBENZOFURAN 5 CARBOXYLIC ACIDY; 7 [4 (P CHLOROPHENYL)AMINOSULPHONYL] 6 HYDROXY 4 METHOXYBENZOFURAN 5 CARBOXYLIC ACID; 7 [4 (P CHLOROPHENYL)SULPHONAMIDO] 6 HYDROXY 4 METHOXYBENZOFURAN 5 CARBOXYLIC ACID; 7 AMINO 6 HYDROXY 4 METHOXYBENZOFURAN 5 CARBOXYLIC ACIDY; ACETIC ACID; AMPHOTERICIN B; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

AGAR DIFFUSION; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MALE; NONHUMAN; ORGAN WEIGHT; RAT; RATING SCALE; SYNTHESIS; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; BACTERIA; BENZOFURANS; COLITIS, ULCERATIVE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LETHAL DOSE 50; LIPOXYGENASE INHIBITORS; MALE; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION; RATS; SALICYLIC ACID; STOMACH;

EID: 77955559140     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.05.071     Document Type: Article

References (39)

1. U. Klotz, and M. Schwab Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease Adv. Drug Deliv. Rev. 57 2005 267 279
2. Y. Jung, H.H. Kim, H. Kim, H. Kong, B. Choi, Y. Yang, and Y. Kim Evaluation of 5-aminosalicytaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis Eur. J. Pharm. Sci. 28 2006 26 33
3. D.R. Friend New oral delivery systems of treatment of inflammatory bowel disease Adv. Drug Deliv. Rev. 57 2005 247 265
4. K.L. Knigge Inflammatory bowel disease Clin. Cornerstone 4 2002 49 57
5. P. Gionchetti, C. Amadini, F. Rizzello, A. Venturi, and M. Campieri Treatment of mild to moderate ulcerative colitis and pouchitis Aliment. Pharmacol. Ther. 16 2002 13 19
6. O.H. Nielsen, and L.K. Munck Drug insight: aminosalicylates for treatment of IBD Nat. Clin. Pract. Gastroenterol. Hepatol. 4 2007 160 170
7. J. Varshosaz, J. Emami, N. Tavakoli, A. Fassihi, M. Minaiyan, F. Ahmadi, and F. Dorkoosh Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis Int. J. Pharm. 365 2009 69 76
8. W. El-Matary, B. Vandermeer, and A.M. Griffiths Methotrexate for maintenance of remission in ulcerative colitis Cochrane Database Syst. Rev. 3 2009 CD007560
9. E.J. Eshuis, W.A. Bemelman, and P.C. Stokkers Infliximab for the treatment of ulcerative colitis Expert Rev. Gastroenterol. Hepatol. 3 2009 219 229
10. H. Mayberry, T. Moshkoyska, and J.F. Mayberry Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitis Inflamm. Bowel Dis. 15 2009 190 192
11. T.H. Joeres-Nquyen-Xuan, S.K. Boehm, L. Joeres, J. Schulze, and W. Kruis Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers Inflamm. Bowel Dis. 16 2010 256 262
12. G.C. Actis, P. Pazienza, and F. Rosina Mesalamine for inflammatory bowel disease: recent reappraisals Inflamm. Allergy Drug Targets 7 2008 1 5
13. Y.Q. Zhong, H.R. Huang, Z.H. Zhu, Q.K. Chen, J. Zhan, and L.C. Xing Effects of sulfasalazine on biopsy mucosal pathologies and histological grading of patients with active ulcerative colitis World J. Gastroenterol. 11 2005 4435 4438
14. A. Jain, Y. Gupta, and S.K. Jain Azo chemistry and its potential for colonic delivery Crit. Rev. Ther. Drug Carrier Syst. 23 2006 349 400
15. S.A. Patil, and A.C. Moss Balsalazide disodium for the treatment of ulcerative colitis Expert Rev. Gastroenterol. Hepatol. 2 2008 177 184
16. S.S. Dhaneshwar, M. Chail, M. Patil, S. Naqvi, and G. Vadnekar Colon-specific mutal prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats Eur. J. Med. Chem. 44 2009 131 142
17. A.A. Abdel-Alim, A.N. El-Shorbaqi, S.G. Abdel-Moty, and H.H. Abdel-Allah Synthesis and anti-inflammatory testing of some new compounds incorporating 5-aminosalicylic acid (5-ASA) as potential prodrugs Arch. Pharm. Res. 28 2005 637 647
18. A.C. Luchini, P. Rodriques-Oris, S.H. Cestari, L.N. Seito, A. Witaicenis, C.H. Pellizzon, and L.C. Stasi Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrbenzenesulphonic acid model of rat colitis Biol. Pharm. Bull. 31 2008 1343 1350
19. V. Deore, N. Yewalkar, D. Bhatia, N. Desai, R.D. Gupte, S.S. Dadarkar, M.G. Jadhav, A.A. Tannu, P. Bhatt, K.V. Nemmani, R.A. Vishwakarma, S. Sharma, A. Roychowdhury, N.M. Dagia, M.R. Bhonde, and S. Kumar Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors Bioorg. Med. Chem. Lett. 19 2009 2949 2952
20. F.A. Ragab, G.S. Hassan, H.A. Yossef, and H.A. Hashem Synthesis of 6- and 9-alkylaminomethyl furoflavones as gastroprotective agents Eur. J. Med. Chem. 42 2007 1117 1127
21. G.O. Dengiz, F. Odabasoglu, Z. Halici, H. Sulevman, E. Cadirci, and Y. Bavir Gastroprotective and antioxidant effects of amiodarone on indomethacin-induced gastric ulcers in rats Arch. Pharm. Res. 30 2007 1426 1434
22. M. Zheng, Z. Zhang, W. Zhu, H. Liu, X. Luo, K. Chen, and H. Jiang Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues Bioorg. Med. Chem. 14 2006 3428 3437
23. J.M. Janusz, P.A. Young, J.M. Ridgeway, M.W. Scherz, K. Enzweiler, L.I. Wu, L. Gan, J. Chen, D.E. Kellstein, S.A. Green, J.L. Tulich, T. Rosario-Jansen, I.J. Magrisso, K.R. Wehmeyer, D.L. Kuhlenbeck, T.H. Eichhold, and R.L. Dobson New cyclooxygenase-2/5-lipoxygenase inhibitors. 3.7-tert-butyl-2,3-dihydro-3,3- dimethylbenzufuran derivatives as gastrointestinal safe anti-inflammatory and analgesic agents: variation at the 5-position J. Med. Chem. 41 1998 3515 3529
24. S.M. Rida, S.A. El-Hawash, H.T. Fahmy, A.A. Hazza, and M.M. El-Meligy Synthesis and in vitro evaluation of some novel benzofuran derivatives as potential anti-HIV-1, anticancer, and antimicrobial agents Arch. Pharm. Res. 29 2006 16 25
25. C. Kirilmis, M. Ahmedzade, S. Servi, M. Koca, A. Kizirgil, and C. Kazaz Synthesis and antimicrobial activity of some novel derivatives of benzofuran: part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives Eur. J. Med. Chem. 43 2008 300 308
26. A. Schonberg, N. Badran, and N.A. Starkowsky Furo-chromones and -Coumarins VII. Degradation of visnagin, Khellin and related substances; experiments with chromic acid and hydrogen peroxide; and a synthesis of Eugenitin J. Am. Chem. Soc. 75 1953 4992 4995
27. C. Musante, L. Fabbrini, and A. Franchi Action of diazo derivatives on visnaginone and its derivatives Farmaco (Pavia), Ed. Sci. 17 1962 526 531
28. G.P. Morris, P.L. Beck, M.S. Herridge, W.T. Depew, M.R. Szewczuk, and J.L. Wallace Hapten-induced model of inflammation and ulceration in the rat colon Gasteroenterology 96 1989 795 803
29. N. Mascolo, A. Izzo, G. Autore, F.M. Maiello, G. Di Carlo, and F. Capsso Acetic acid-induced colitis in normal and essential fatty acid deficient rats J. Pharmacol. Exp. Ther. 272 1995 469 475
30. R. Fabia, R. Willén, A. Ar'Rajab, R. Andersson, B. Ahrén, and S. Bengmark Acetic acid-induced colitis in the rat: a reproducible experimental model of acute ulcerative colitis Eur. Surg. Res. 24 1992 211 225
31. H.H. Hagar, A. El-Medany, E. El-Eter, and M. Arafa Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats Eur. J. Pharmcol. 554 2007 69 77
32. G.E. Harisa, O.M. Abo-Salem, S.M. El-Sayed, E.I. Taha, and N. El-Halwany L-arginine augments the antioxidant effect of garlic against acetic acid-induced ulcerative colitis in rats Pak. J. Pharm. Sci. 22 2009 373 380
33. W.B. Buck, G.D. Osweiter, and A.G. Van Gelder Clinical and Diagnostic Veterinary Toxicology second ed. 1976 Kendall/Hunt Publishing Co. Iowa pp. 5211-5215
34. N. Mutch A new sulphonamid (Sulphonamide E.O.S.): its pharmacology, chemotherapy, and curative value in meningococcal meningitis Br. Med. J. 2 1941 503 507
35. C.H. Collins Microbiological Methods 1967 Butterworths London pp. 364
36. Molecular Operating Environment (MOE) Version 2008.10 2008 Chemical Computing Group, Inc. Montreal, Quebec, Canada http://www.chemcomp.com
37. G.E. Paget, and J.M. Barnes Toxicity tests D.R. Lautrance, A.L. Bacharach, Evaluation of Drug Activities: Pharmacometrics 1964 Academic Press London and New York 135 166
38. D.J. Finney 'Statistical Methods in Biological Assay' 1964 Charles Griffin and Company Ltd London pp. 597
39. M. Minalan, A.R. Ghannadi, and A.R. Karimzadeh Anti-ulcerogenic effects of ginger (rhizome of Zingiber Officinale Roscoe) on cystemine induced duodenal ulcer in rats DARU 14 2006 97 101